SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TOSHI

TOSHI is trending as investors aggressively discuss a potential breakout and short squeeze, driven by anticipation surrounding its integration with OpenHuman and the broader potential of the Base ecosystem. The community remains highly active and vocal about their conviction in the project, often highlighting its large wallet holder base and current accumulation levels as a key setup for significant upside movement.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Branded and ImprimisRx. The Branded segment includes activities of the company’s FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain branded products. The ImprimisRx segment represents activities in the company’s ophthalmology-focused pharmaceutical compounding business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is trending as investors gear up for the upcoming earnings report, with the community actively debating the company's forward-looking guidance strategy and the long-term potential of its expanding ophthalmic product portfolio. Discussions are centered on the significant growth prospects for key drugs like Vevye and Iheezo, fueling speculation about institutional positioning and the potential for a short squeeze as the market digests the company's path toward long-term scale.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending due to the company's recent regulatory success in gaining European approval to use commercially manufactured GP2 peptide in the ongoing FLAMINGO-01 Phase 3 trial. Community discussion is heavily focused on the trial's expanded footprint and potential for accelerated data readouts, with many investors anticipating that these operational de-risking events and the upcoming ASCO conference could act as catalysts for a re-rating.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera Biologics is experiencing a surge in investor interest and volatility driven by its transition into a clinical-stage biotech and high-profile partnerships, such as the major TCE discovery deal with Jazz Pharmaceuticals. The community is actively discussing the stock's role as a long-term play on AI-driven drug discovery, with sentiment split between institutional investors betting on upcoming Phase 2 clinical readouts and skeptical retail traders focused on past stock performance and short interest.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing significant market attention and heightened trading volume as investors react to the FDA's acceptance of sNDA submissions for its Duchenne muscular dystrophy therapies, fueling widespread speculation regarding potential buyout activity. While the community remains deeply divided by extreme volatility and long-standing frustration with management, the primary discussion centers on whether this movement signals a long-awaited re-rating or another cycle of manipulation by short sellers.

Redwire Corp. engages in the development and provision of space and defense technologies and mission-critical solutions for government, commercial, and civil customers. Its offerings include spacecraft platforms, space infrastructure, avionics, sensors and payloads, power generation systems, radio frequency systems, microgravity research and manufacturing technologies, autonomous systems, optical sensors, and digital engineering solutions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire Corp is seeing intense community debate following recent contract wins, including a multi-million dollar follow-on award for its Stalker UAS program, while the stock faces significant downward volatility alongside the broader space sector. Investors are actively discussing the impact of recent insider buying, strategic advisory appointments for the SpaceMD division, and the potential for a long-term defense tech moat, while traders express frustration over recent price corrections and concerns regarding dilution.

General Fusion Group Ltd. engages in the fusion industry, developing practical magnetized target fusion technology that is designed to address the key barriers to commercializing fusion. The company is headquartered in Richmond, Canada.

General Fusion Group Ltd.

General Fusion is capturing investor attention following its recent Nasdaq debut, with community discussion centered on its long-term potential in the fusion energy sector and comparisons to competing peers. While some market participants are optimistic about its proprietary technology and backing, others are debating the company's ambitious commercialization timelines and the broader risks associated with pre-revenue energy ventures.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark Inc. is currently attracting intense investor attention following a major 20-year infrastructure lease agreement, which the community views as a pivotal shift from pure bitcoin mining toward high-value AI compute and data center operations. Investors are actively debating the company's valuation, potential hyperscaler partnerships, and execution timelines, as they weigh the significant contracted revenue against concerns regarding capital-intensive build-outs and broader sector volatility.

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Nuvation Bio Inc - Ordinary Shares - Class A

Nuvation Bio is trending as investors digest news of a strategic collaboration with Thermo Fisher Scientific for IBTROZI manufacturing alongside ongoing community discussion regarding the firm's robust clinical pipeline, particularly safusidenib's potential in the glioma market. Shareholders are actively debating the stock's valuation relative to competitors, with many pointing to significant institutional accumulation and the leadership of CEO David Hung as indicators of long-term upside potential despite recent price volatility.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio remains a central focus for retail traders who are actively debating the likelihood of a major partnership or acquisition, particularly as the community monitors potential global expansion and the integration of the Leonardo manufacturing system. Much of the discourse centers on intense short-selling activity and the anticipation of upcoming catalyst announcements, with many investors maintaining long positions based on their conviction in the companys immunotherapy pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?

Dianthus Therapeutics stock climbs 89% in six months as claseprubart advances across key autoimmune studies. Strong cash position supports development into 2030.

DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results

Equity

In the first part of the CIDP study, 75% of the initial group of patients showed meaningful improvement after receiving claseprubart, Dianthus said.

Why Is Dianthus Therapeutics Stock Trading Higher On Friday?

Dianthus reports 75% responder rate for claseprubart in CIDP, while analysts say Sanofi's riliprubart faces rising risks after MOBILIZE.read more...

Dianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product Pipeline

Dianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product Pipeline...

Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish

Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish...

Wedbush Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price

Wedbush raised their price target on Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an 'outperform' rating in a report on Wednesday...

Dianthus Therapeutics (NASDAQ:DNTH) Releases Earnings Results, Beats Expectations By $0.25 EPS

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts...

Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates

Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of +27.04% and -15.05%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Dianthus Therapeutics (DNTH) to Release Earnings on Monday

Dianthus Therapeutics (NASDAQ:DNTH) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-dianthus-therapeutics-inc-stock...

Short Interest in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Decreases By 27.6%

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) was the recipient of a large decrease in short interest in the month of April. As of April 15th, there was short interest totaling...

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.

Dianthus Therapeutics Inc

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is pacing for a losing week as a semiconductor ($SMH) sell-off has dragged the market lower amid growing doubts about AI spending. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

DNTHDianthus Therapeutics Inc

Fundamentals

Latest DNTH News